Introduction {#Sec1}
============

Basal--bolus insulin therapy (BBT) is the most effective approach to ameliorate hyperglycemia, but has adverse effects, such as weight gain and hypoglycemia, which may increase the incidence of cardiovascular events. During the daytime, a patient can become aware of the symptoms of hypoglycemia, such as palpitations, cold sweats, etc. However, nocturnal hypoglycemia is difficult to notice for a patient. With continuous glucose monitoring (CGM), nocturnal hypoglycemia, including asymptomatic hypoglycemia, can be detected with high precision \[[@CR1]\]. Because of a flatter pharmacokinetics (PK) scope, therapy with insulin glargine 100 units/mL (Gla-100) was reported to significantly reduce the incidence of severe symptomatic nocturnal hypoglycemia, compared with therapy with neutral protamine Hagedorn insulin \[[@CR2]\]. However, our previous investigation on hospitalized type 2 diabetic patients with tightly controlled blood sugar under BBT showed that Gla-100 induced asymptomatic hypoglycemia, confirmed by CGM, in high frequency \[[@CR3]\].

On the other hand, insulin glargine 300 units/mL (Gla-300) is a new basal insulin analogue that has a prolonged effect and flatter PK profile than Gla-100 \[[@CR4]--[@CR6]\]. Previous studies on type 2 diabetic patients treated with BBT, basal supported oral therapy, or oral antidiabetic agents alone showed that compared with Gla-100, Gla-300 could control HbA1c at the same efficacy and with consistently less risk of nocturnal hypoglycemia at 3:00, as estimated by symptoms and self-monitored plasma glucose \[[@CR7]--[@CR12]\]. Two studies that employed CGM demonstrated the safety and efficacy of Gla-300 in type 1 diabetics \[[@CR13], [@CR14]\]; however, research on CGM in type 2 diabetic patients has not been reported.

In the present study, we evaluated by CGM the efficacy and safety of BBT with Gla-300 in comparison with that with Gla-100 in well-controlled type 2 diabetic patients at the end of short-term hospitalization.

Methods {#Sec2}
=======

Subjects {#Sec3}
--------

In the present study, we included the type 2 diabetes patients, who consulted the outpatient clinic of Nippon Medical School Chiba Hokusoh Hospital from November 2014 to October 2016 if they had HbA1c level ≥ 10% on the first visit and had consented for hospitalization for diabetic control. The hospital is one of the three base hospitals in a locality with a population of 700,000 that consists of several cities, towns, and villages near the metropolitan city of Tokyo, Japan. The clinic provides care to patients with diabetes referred by general practitioners or other departments in the hospital because the diabetes was difficult to control because of poor metabolic control or unstable complications. The socioeconomic status of the patients was previously reported \[[@CR15]\]. Subjects were excluded if they had been previously treated with insulin; were positive for anti-glutamic acid decarboxylase antibody; or had history or evidence of recent myocardial infarction, heart failure, cerebrovascular disease, endocrine disease, or any carcinoma.

A total of 54 patients with type 2 diabetes were assessed for eligibility. Patients were excluded because of the presence of concomitant disease (*n* = 7), insulin use (*n* = 3), and rejection of approval (*n* = 4). The remaining 40 patients, aged 20--75 years, were enrolled in an unblinded, randomized study (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Participant flow

Study Protocol and Treatment {#Sec4}
----------------------------

The study protocol was approved by the ethics committee of Nippon Medical School Chiba Hokusoh Hospital (No.527009) and was registered at UMIN Clinical Trials Registry (UMIN000023360). All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from all patients for inclusion in the study. On admission, all subjects stopped taking oral antidiabetic agents, received diet therapy, and were randomly assigned using a table of random sampling numbers (block size of 4) to receive BBT with insulin glulisine plus either Gla-100 (Gla-100 group, *n* = 20) or Gla-300 (Gla-300 group, *n* = 20).

In both groups, the dose of insulin injection was adjusted by the attending physicians to maintain pre-meal blood glucose levels within 100--120 mg/dL. Within 3 days after admission, an ophthalmologist checked each patient for the presence of diabetic retinopathy; if needed, fluorescent fundus angiography and retinal laser photocoagulation were immediately performed.

To assess the daily profile of plasma glucose and C-peptide (CPR), blood specimens were obtained from the cubital vein before and every 2 h after each meal (8:00, 10:00, 12:00, 14:00, 18:00, and 20:00); at night (23:00); in the early morning (3:00); and on the next morning (8:00). These processes were performed on the first and second days after admission and on the last 2 days before discharge. Analysis of daily profile was performed for the whole day; during the daytime including 8:00, 10:00, 12:00, 14:00, 18:00, and 20:00; and at night including 23:00, 3:00, and 8:00 of the next morning. The blood samples collected between 7:30 and 14:00 were immediately centrifuged, whereas those collected between 17:00 and 3:00 were stored at 4°C and centrifuged the next morning.

Daily blood glucose profiles on the last 2 days before discharge were assessed by CGM (iPro™2; Medtronic, Minneapolis, MN, USA). To assess daily glycemic variability, the mean glucose level, standard deviation (SD) of the daily glucose, and mean amplitude of glycemic excursion (MAGE) \[[@CR16]\] were calculated. Hypoglycemia was defined as a CGM value of lower than 70 mg/dL. A hypoglycemic episode that occurred anytime from 0:00 to 8:00 was defined as nocturnal hypoglycemia.

Statistical Analysis {#Sec5}
--------------------

All analyses except two-way repeated measures analysis of variance were performed using the JMP 12.2 software (SAS Institute, Cary, NC). Values were presented as mean ± SD or number. Statistical analyses of the gender differences and complications of diabetes at baseline were performed using the *χ*^2^ test. The significance of the differences between two groups with regard to the baseline characteristics and parameters of glycemic control before discharge was analyzed by Student's *t* test. Two-way repeated measures analysis of variance of the daily profile of PG and CPR were performed using IBM SPSS Statistics software (version 22; IBM Japan, Tokyo, Japan). A *P* value of less than 0.05 was considered statistically significant.

Results {#Sec6}
=======

The present study enrolled 40 patients, with mean age of 58 ± 14 years, who had type 2 diabetes for a mean duration of 5 ± 6 years; 72.5% were men (Table [1](#Tab1){ref-type="table"}). Four patients, two from each group, dropped out because of the detection of malignancy or withdrawal of approval (Fig. [1](#Fig1){ref-type="fig"}). There were no significant differences in the baseline characteristics between the two treatment groups.Table 1Baseline parameters of glycemic control, complications, and medications before admissionParameterGla-100Gla-300*P* valueNumber of patients (men)20 (13)20 (16)NSAge (years)61 ± 1254 ± 15NSDuration of diabetes (years)\*6 ± 75 ± 6NSBMI (kg/m^2^)26.1 ± 3.925.5 ± 6.3NSDesignated dietary calorie (kcal/day)1594 ± 2311661 ± 217NSFPG (mg/dL)198 ± 54199 ± 51NSHbA1c (%)\*\*11.1 ± 2.111.0 ± 2.2NSGA (%)27 ± 6.828.6 ± 9.9NSALT (mg/dL)29 ± 1723 ± 9NSAST (mg/dL)30 ± 2126 ± 13NSGGT (mg/dL)57 ± 7243 ± 33NSCre (mg/dL)0.71 ± 0.210.73 ± 0.29NSU-CPR (μg/day)116 ± 67.5133 ± 65NSComplication Absent Achilles tendon reflex (*n*)910NS U-Alb (mg/day)94.4 ± 188311.2 ± 865.2NS Diabetic retinopathy (DR)\*\*\*NS  None (*n*)1411  Simple DR (*n*)58  Preproliferative DR (*n*)11  Proliferative DR (*n*)00Medication before admission\*NS Sulfonylureas (*n*)44 Biguanides (*n*)34 Thiazolidinediones (*n*)10 Alpha-glucosidase inhibitors (*n*)31 Dipeptidyl peptidase-4 inhibitor (*n*)54Data are expressed as mean ± standard deviation or number*Gla-100* insulin glargine 100 units/mL, *Gla-300* insulin glargine 300 units/mL, *NS* not significant, *BMI* body mass index, *FPG* fasting plasma glucose, *HbA1c* hemoglobin A1c, *GA* glycated albumin, *AST* aspartate aminotransferase, *ALT* alanine aminotransferase, *GGT* gamma glutamyl transpeptidase, *Cre* creatinine, *U-CPR* urinary C-peptide immunoreactivity, *U-Alb* urinary albumin\*Reported by the general practitioners who referred the patients\*\*HbA1c levels were determined by high-performance liquid chromatography using an HLC723G8 (Tosoh, Co., Tokyo, Japan) and presented as the equivalent National Glycohemoglobin Standardization Program values\*\*\*Evaluated by ophthalmologists who performed fundoscopy after pupillary dilatation following the Davis classification

The duration of hospitalization was 15 ± 2 and 15 ± 1 days in the Gla-100 and Gla-300 groups, respectively. The required insulin doses to maintain normoglycemia were not different between the two groups; specifically, the required doses for Gla-100 and Gla-300 were 10 ± 5 and 10 ± 6 units, respectively, before breakfast; 3 ± 2 and 2 ± 2 units, respectively, before lunch; 9 ± 3 and 9 ± 4 units, respectively, before dinner; and 13 ± 7 and 15 ± 10 units, respectively, at bedtime.

The daily profiles of plasma glucose and CPR were not significantly different between the two groups upon admission, but were significantly lower in the Gla-100 group than in the Gla-300 group only at night before discharge (Fig. [2](#Fig2){ref-type="fig"} and Table [2](#Tab2){ref-type="table"}). The mean glucose (119 ± 15 and 124 ± 20 in Gla-100 and Gla-300 group, respectively), SD (33 ± 11 and 31 ± 12), and MAGE (79 ± 36 and 74 ± 27) levels calculated with CGM data before discharge were not significantly different between the BBT groups. However, in both groups, the nadir of the blood glucose profile was around 0:00--1:00 a.m. (Fig. [3](#Fig3){ref-type="fig"}). The frequency of nocturnal hypoglycemia was significantly lower in the Gla-300 group than in the Gla-100 group (1.2% ± 3.6% versus 10.7% ± 18.4%, *P* = 0.039) (Figs. [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}). No patients reported nocturnal hypoglycemic symptoms, such as night sweats and nightmares, during the admission.Fig. 2Daily profiles of plasma glucose and serum C-peptide. Daily profiles of plasma glucose (**a**, **c**) and serum C-peptide (**b**, **d**) in the insulin glargine 100 units/mL group (open triangles and dashed line; *n* = 18) and in the insulin glargine 300 units/mL group (filled circles and solid line; *n* = 18) on admission (**a**, **b**) and upon discharge (**c**, **d**) Table 2Analysis of the daily profiles of plasma glucose and serum C-peptideWhole dayDaytimeNightTreatmentTimeTime × treatmentTreatmentTimeTime × treatmentTreatmentTimeTime × treatmentOn admission Plasma glucose  *F*0.020230.210.058340.120.0065300.11  *P* (95% CI)0.89 (− 50, 57)\< 0.0010.900.81 (− 53, 67)\< 0.0010.980.94 (− 47, 43)\< 0.0010.82 Serum CPR  *F*1.2270.870.98510.891.5412.9  *P* (95% CI)0.29 (− 1.3, 0.41)\< 0.0010.450.33 (− 1.6, 0.54)\< 0.0010.440.30 (− 1.0, 0.26)\< 0.0010.079Before discharge Plasma glucose  *F*3.1291.350.98460.675.67.83.2  *P* (95% CI)0.088 (− 22, 1.6)\< 0.0010.260.33 (− 20, 6.7)\< 0.0010.560.023 (− 30, − 2.4)0.00170.069 Serum CPR  *F*3.9161.072.6281.16.5124.2  *P* (95% CI)0.058 (− 1.3 0.023)\< 0.0010.350.12 (− 1.6, 0.19)\< 0.0010.330.0047 (− 0.93, − 0.18)\< 0.0010.027Repeated multivariate analyses of variance were performed for the whole day (all point); during the daytime (8:00, 10:00, 12:00, 14:00, 18:00, and 20:00); and at night (23:00, 3:00, and 8:00 of the next day). The values of statistics (*F*), *P* value (*p*), and 95% confidence interval (95% CI) determine differences according to insulin treatment group (treatment), time course (time), and the interaction of time course and treatment group (time × treatment), as calculated by repeated multivariate analysis of variance Fig. 3Continuous glucose monitoring values before discharge. The mean values (solid black line) and the range of standard deviation (gray area) of the continuous glucose monitoring data before discharge in the **a** insulin glargine 100 units/mL and **b** insulin glargine 300 units/mL groups Fig. 4Frequency of nocturnal hypoglycemia. Data are expressed as mean ± standard deviation. Gla-100, insulin glargine 100 units/mL; Gla-300, insulin glargine 300 units/mL. \**P* \< 0.05 versus the Gla-100 group

No adverse events, such as symptomatic hypoglycemia, injection-site reaction, infection gastrointestinal events, musculoskeletal complaints, or newly developed blood test abnormality during admission, were reported.

Discussion {#Sec7}
==========

The present study, which employed CGM and serial phlebotomies to compare Gla-300 and Gla-100, revealed no difference in the required dose of insulin and time to achieve normoglycemia. However, the frequency of nocturnal hypoglycemia was significantly lower with Gla-300 than with Gla-100. In similar studies, \[[@CR7]--[@CR9], [@CR11], [@CR12]\] the basal insulin dose required to achieve the same fasting plasma glucose had a non-significant and slight tendency to be higher with Gla-300 than with Gla-100. The required dose of prandial insulin was not different between the two groups.

The higher required dose of Gla-300 probably reflects the slightly lower serum glargine concentration at 11 h after administration, which could be explained by some PK--pharmacodynamics (PD) studies that showed reduced absorption of the more concentrated Gla-300 insulin in subcutaneous administration, even at equal doses with Gla-100 \[[@CR4]--[@CR6]\].

In the present study, the nocturnal plasma glucose and CPR levels estimated by serial phlebotomies were significantly lower in Gla-100 than in Gla-300, probably owing to the stronger glucose-lowering effect of the infused Gla-100 in the nocturnal phase. The CGM-estimated nocturnal glucose levels in the Gla-100 group were lower in the hypoglycemic range at a high frequency than those in the Gla-300 group.

The reduction of frequency in the nocturnal hypoglycemia in type 2 diabetic patients in this study was the same as the results shown in phase 3a EDITION programs that compared Gla-300 with Gla-100 \[[@CR7]--[@CR12]\]. The CGM data in this study showed that the nadir of blood glucose profile was around 0:00--1:00 a.m., which is about 4 h after the injection of basal insulin. In some PK--PD studies, the peak glucose-lowering effect and serum glargine concentration were observed 4 h after the BBT administration of both Gla-100 and Gla-300 at 21:00 \[[@CR4]--[@CR6]\]. In the current study, no patients with nocturnal hypoglycemia reported symptoms or showed elevation of fasting plasma glucose, such as that seen in the Somogyi phenomenon \[[@CR17]\]. Similar to previous reports, our study suggested that detection of nocturnal hypoglycemia could be challenging without the use of CGM.

Hypoglycemia is known to activate the sympathetic nerves to ameliorate hypoglycemia \[[@CR18], [@CR19]\]; however, this might worsen heart failure. In some clinical trials, hypoglycemia significantly increased the mortality of patients with type 2 diabetes \[[@CR20], [@CR21]\]. Administration of beta blocker was reported to reduce the incidence of hospitalization for heart failure \[[@CR22]\], whereas intensive glycemic control increased the incidence of cardiovascular deaths \[[@CR23]\]. The EMPA-REG OUTCOME study demonstrated that the sodium-glucose cotransporter 2 inhibitor (SGLT2I) reduced the incidence of cardiovascular mortality and hospitalization for heart failure in patients with type 2 diabetes \[[@CR24]\]. We previously reported that SGLT2I has a preventive effect on nocturnal hypoglycemia in type 2 diabetic patients on BBT \[[@CR3]\]. This preventive effect may have mediated the favorable results for the cardiovascular disease shown in the EMPA-REG OUTCOME study.

Because of the long PD of insulin degludec, another kind of new basal insulin analogue, a longer time is required to achieve a stable serum concentration of insulin degludec; insulin degludec also takes a long time to stabilize fasting plasma glucose after changing the dose of insulin compared with Gla-100. In the present study, the duration of hospitalization depended on the time to achieve normal glycemic control, regardless of the BBT regimen used. These data suggested that Gla-300 can achieve a stable fasting glucose as fast as Gla-100.

This study has some limitations. The unblinded trial and the small sample size might impact the results in this study. Because physical activity during the admission was not assessed, a confounding bias might be introduced. We could not find previous studies about the comparison between Gla-100 and Gla-300 with tightly controlled blood glucose levels and diet therapy in hospitalization; hence, we could not perform a power analysis to determine the sample size. However, although the sample size is small, the preventive effect of Gla-300 on nocturnal hypoglycemia in the present study is similar to the results of previous studies about the comparison between Gla-100 and Gla-300 at an outpatient clinic with a large sample size. Therefore, we believe that the results of the present study are conclusive. Further investigations on the possible complications of nocturnal hypoglycemia are required.

Conclusion {#Sec8}
==========

This study documented that Gla-300 had similar efficacy with Gla-100 in controlling blood glucose level, but with less frequent episodes of nocturnal hypoglycemia in type 2 diabetic patients under the tightly controlled diet therapy and careful monitoring of blood glucose in short-term hospitalization.
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